23 terminated. 23 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Terminated 23 |
| Phase 2 | 4 | Terminated 4 |
Follow Vector Borne Diseases: new trials by email Literature Review of Vector Borne Diseases trials Research Report on Vector Borne Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults Oleylphosphocholine - Leishmaniasis | Phase 1 | Terminated | University Hospital Tuebingen | 13 | 2023-06-21 | 2024-03-12 |
| A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline - Malaria, Malaria,Falciparum | Phase 1 | Terminated | Sanaria Inc. | 31 | 2022-12-06 | 2024-11-25 |
| Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model AT-752, Placebo Comparator - Dengue | Phase 1 | Terminated | Atea Pharmaceuticals, Inc. | 5 | 2022-04-22 | 2023-04-21 |
| Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug AWZ1066S, Placebo - Filariasis, Lymphatic, Onchocerciasis | Phase 1 | Terminated | Liverpool School of Tropical Medicine | 30 | 2021-12-10 | 2023-09-21 |
| Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania. Pfs25-IMX313 (10ug)/Matrix-M (50ug), Pfs25-IMX313 (50ug)/Matrix-M (50ug), Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug) - Malaria,Falciparum | Phase 1 | Terminated | University of Oxford | 34 | 2021-05-25 | 2025-01-27 |
| Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants GSK3494245, Placebo - Leishmaniasis | Phase 1 | Terminated | GlaxoSmithKline | 59 | 2020-09-29 | 2026-05-01 |
| A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19 Galidesivir, Placebo - COVID-19, Yellow Fever | Phase 1 | Terminated | BioCryst Pharmaceuticals | 24 | 2020-04-09 | 2021-05-27 |
| VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine Pfs25-IMX313/Matrix-M1 - Malaria,Falciparum | Phase 1 | Terminated | University of Oxford | 1 | 2019-09-27 | 2020-09-29 |
| Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects GSK3186899, Placebo - Leishmaniasis | Phase 1 | Terminated | GlaxoSmithKline | 25 | 2019-04-30 | 2023-02-27 |
| Safety and Pharmacokinetics Study of DM1157 to Treat Malaria DM1157, Placebo - Malaria | Phase 1 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 50 | 2018-07-31 | 2021-07-23 |
| Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution - Viral Infection | Phase 1 | Terminated | Emergent BioSolutions | 7 | 2016-05-27 | 2024-03-18 |
| A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection DSM265, OZ439 - Malaria | Phase 1 / Phase 2 | Terminated | Medicines for Malaria Venture | 16 | 2015-10-01 | 2020-06-05 |
| Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos KAE609, Piperaquine Phosphate - Plasmodium Falciparum Malaria | Phase 1 | Terminated | Novartis Pharmaceuticals | 8 | 2015-07-01 | 2019-07-23 |
| MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants MMV390048 20mg - Malaria, Falciparum | Phase 1 | Terminated | Medicines for Malaria Venture | 6 | 2014-10-01 | 2020-06-09 |
| Safety, Tolerability & Pharmacokinetics (PK) of Co-administered Single Doses of OZ439 and Mefloquine (MQ) in Healthy Volunteers OZ439 100mg, OZ439 400mg, MQ 250 mg, single dose - Malaria | Phase 1 | Terminated | Medicines for Malaria Venture | 25 | 2012-08-01 | 2015-04-16 |
| Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food Tablets Fexinidazole, Placebo - Trypanosomiasis, African | Phase 1 | Terminated | Drugs for Neglected Diseases | 30 | 2011-09-01 | 2017-03-31 |
| Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria Sevuparin sodium + atovaquone/proquanil, atovaquone/proquanil - Malaria, Falciparum | Phase 1 / Phase 2 | Terminated | Modus Therapeutics AB | 53 | 2011-09-01 | 2014-08-19 |
| Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine p52-/p36- GAP Vaccine, p52-p36- GAP Vaccine - Malaria | Phase 1 / Phase 2 | Terminated | Seattle Children's Hospital | 6 | 2010-03-01 | 2019-10-28 |
| A First Time in Human Study in Healthy Volunteers to Investigate a New Medicine to Treat Malaria GSK932121; Rosiglitazone; Rosuvastatin - Malaria | Phase 1 | Terminated | GlaxoSmithKline | 12 | 2008-12-11 | 2017-08-03 |
| Chlorproguanil-Dapsone in Pregnant Women chlorproguanil-dapsone - Malaria | Phase 1 | Terminated | Centers for Disease Control and Prevention | 132 | 2005-07-01 | 2025-04-20 |
Showing 20 of 23. Sign in to see all of them.
Malaria (9) · Malaria, Falciparum (8) · Leishmaniasis (3) · Dengue (2) · Arbovirus Infections (1) · COVID-19 (1) · Elephantiasis, Filarial (1) · Flaviviridae Infections (1) · Flavivirus Infections (1) · Hemorrhagic Fevers, Viral (1) · Leishmaniasis, Visceral (1) · Onchocerciasis (1) · RNA Virus Infections (1) · Trypanosomiasis, African (1) · Virus Diseases (1)
Infections (23) · Parasitic Diseases (19) · Mosquito-Borne Diseases (18) · Protozoan Infections (18) · Euglenozoa Infections (5) · Malaria (4) · Skin Diseases (4) · Skin Diseases, Infectious (4) · Skin Diseases, Parasitic (4) · Skin and Connective Tissue Diseases (4) · Arbovirus Infections (3) · Flaviviridae Infections (3) · Flavivirus Infections (3) · RNA Virus Infections (3)
Matrix-M (2) · artefenomel (2) · AT-752 (1) · Atovaquone (1) · DSM265 (1) · GSK3186899 (1) · MMV390048 (1) · Malaria Vaccines (1) · NITD 609 (1) · Rosiglitazone (1) · Rosuvastatin Calcium (1) · Saline Solution (1) · Solutions (1) · chloroguanil, dapsone drug combination (1) · fexinidazole (1)
GlaxoSmithKline (3) · Medicines for Malaria Venture (3) · University of Oxford (2) · AB Foundation (1) · Atea Pharmaceuticals, Inc. (1) · BioCryst Pharmaceuticals (1) · Centers for Disease Control and Prevention (1) · Drugs for Neglected Diseases (1) · Emergent BioSolutions (1) · Liverpool School of Tropical Medicine (1) · Modus Therapeutics AB (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis Pharmaceuticals (1) · Sanaria Inc. (1) · Sarepta Therapeutics, Inc. (1)
United States (5) · Australia (4) · United Kingdom (4) · Brazil (2) · France (1) · Germany (1) · Mali (1) · South Africa (1) · Tanzania (1) · Thailand (1)
Angela Minassian (1) · Angela Minassian, PhD (1) · Anna Leitgeb, PhD (1) · Blaise Genton, MD PhD (1) · Esper Kallas, MD, PhD (1) · Feiko ter Kuile, MD, PhD (1) · Graham Devereux, MD (1) · James McCarthy, Dr. (1) · James McCarthy, MD FRACP (1) · James McCarthy, Prof (1) · Karen I Barnes (1) · Kassoum Kayentao, MD, MSPH (1) · Kirsten E Lyke, MD (1) · Lionel Hovsepian, MD (1)
PMID 17925866, PMID 18060072, PMID 24029408, PMID 27930660, PMID 29244851, PMID 30858218, PMID 31932368, PMID 32479608, PMID 33199389, PMID 34179977, PMID 35184256, PMID 38924387, PMID 40098097, PMID 42127151
2019 (1), 272201300017C-18-0-1 (1), U44AI167783 (1)